The Impact of Exacerbation Frequency on Clinical and Economic Outcomes in Swedish COPD Patients: The ARCTIC Study

References

• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128. doi:10.1016/S0140-6736(12)61728-0
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [updated 2019]; 2019.
   Google Scholar
• Blasi F, Cesana G, Conti S, et al. The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PLoS One. 2014;9(6):e101228. doi:10.1371/journal.pone.0101228
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa0909883
   PubMed Web of Science ®Google Scholar
• Celli BR, MacNee W, Force AET. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–946. doi:10.1183/09031936.04.00014304
   PubMed Web of Science ®Google Scholar
• Dal Negro R. Optimizing economic outcomes in the management of COPD. Int J Chron Obstruct Pulmon Dis. 2008;3(1):1–10. doi:10.2147/COPD.S671
   PubMedGoogle Scholar
• Dalal AA, Christensen L, Liu F, et al. Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis. 2010;5:341–349. doi:10.2147/COPD.S13771
   PubMedGoogle Scholar
• Socialstyrelsen (The Swedish National Board of Health and Welfare); 2017. Available from: http://www.socialstyrelsen.se/register. Accessed January 07, 2017.
   Google Scholar
• Toy EL, Gallagher KF, Stanley EL, et al. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD. 2010;7(3):214–228. doi:10.3109/15412555.2010.481697
   PubMedGoogle Scholar
• Statistics Sweden [webpage on the Internet]. Longitudinal Integration Database for Health Insurance and Labour Market Studies [LISA by Swedish acronym 2004]. Available from: https://www.scb.se/en/services/guidance-for-researchers-and-universities/SSLidfhialmsLbSaAa.v-m-fl-rl-i-f-h-i-a-l-s-lLaJ. Accessed March 05, 2021
   Google Scholar
• Santibanez M, Garrastazu R, Ruiz-Nunez M, et al. Predictors of hospitalized exacerbations and mortality in chronic obstructive pulmonary disease. PLoS One. 2016;11(6):e0158727. doi:10.1371/journal.pone.0158727
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–126. doi:10.1016/S2213-2600(18)30006-7
   PubMed Web of Science ®Google Scholar
• Pascoe S, Barnes N, Brusselle G, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7(9):745–756. doi:10.1016/S2213-2600(19)30190-0
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Kostikas K, Fang J, et al. Evaluation of exacerbations and blood eosinophils in UK and US COPD populations. Respir Res. 2019;20(1):178. doi:10.1186/s12931-019-1130-y
   PubMed Web of Science ®Google Scholar
• Läkemedelverkets Medical Products Agency (Sweden): Läkemedelverkets expert panel. [Farmakologisk behandling av kroniskt obstruktiv lungsjukdom (KOL)–behandlingsrekommendationer]. Available from: https://www.lakemedelsverket.se/sv.SMALKolKb. Accessed March 5, 2021. Swedish.
   Google Scholar
• Sulku J, Janson C, Melhus H, et al. A cross-sectional study assessing appropriateness of inhaled corticosteroid treatment in primary and secondary care patients with COPD In Sweden. Int J Chron Obstruct Pulmon Dis. 2019;14:2451–2460. doi:10.2147/COPD.S218747
   PubMed Web of Science ®Google Scholar
• Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977;1(6077):1645–1648. doi:10.1136/bmj.1.6077.1645
   PubMed Web of Science ®Google Scholar
• Kesten S, Celli B, Decramer M, et al. Adverse health consequences in COPD patients with rapid decline in FEV1–evidence from the UPLIFT trial. Respir Res. 2011;12:129. doi:10.1186/1465-9921-12-129
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852. doi:10.1136/thorax.57.10.847
   PubMed Web of Science ®Google Scholar
• Dalal AA, Patel J, D’Souza A, et al. Impact of COPD exacerbation frequency on costs for a managed care population. J Manag Care Spec Pharm. 2015;21(7):575–583. doi:10.18553/jmcp.2015.21.7.575
   PubMed Web of Science ®Google Scholar
• Patel JG, Coutinho AD, Lunacsek OE, et al. COPD affects worker productivity and health care costs. Int J Chron Obstruct Pulmon Dis. 2018;13:2301–2311. doi:10.2147/COPD.S163795
   PubMed Web of Science ®Google Scholar
• Lisspers K, Johansson G, Jansson C, et al. Improvement in COPD management by access to asthma/COPD clinics in primary care: data from the observational PATHOS study. Respir Med. 2014;108(9):1345–1354. doi:10.1016/j.rmed.2014.06.002
   PubMed Web of Science ®Google Scholar
• Stallberg B, Janson C, Johansson G, et al. Management, morbidity and mortality of COPD during an 11-year period: an observational retrospective epidemiological register study in Sweden (PATHOS). Prim Care Respir J. 2014;23(1):38–45. doi:10.4104/pcrj.2013.00106
   PubMedGoogle Scholar
• Gibson PG, McDonald VM. Asthma-COPD overlap 2015: now we are six. Thorax. 2015;70(7):683–691. doi:10.1136/thoraxjnl-2014-206740
   PubMed Web of Science ®Google Scholar
• Kumbhare S, Pleasants R, Ohar JA, et al. Characteristics and Prevalence of Asthma/Chronic Obstructive Pulmonary Disease Overlap in the United States. Ann Am Thorac Soc. 2016;13(6):803–810. doi:10.1513/AnnalsATS.201508-554OC
   PubMed Web of Science ®Google Scholar
• Larsson K, Janson C, Stallberg B, et al. Impact of COPD diagnosis timing on clinical and economic outcomes: the ARCTIC observational cohort study. Int J Chron Obstruct Pulmon Dis. 2019;14:995–1008. doi:10.2147/COPD.S195382
   PubMed Web of Science ®Google Scholar